No Data
Morgan Stanley Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $42
Hims & Hers Health: Strong App Download Momentum and New Product Launches Drive Buy Recommendation
Hims & Hers Health Shares Fall After Downgrade From Citigroup
Express News | Watching Hims & Hers Health; Traders Circulate Popular Retail Trading Newsletter Saying Stock Is Poised For A Major Surge In 2025
HIMS Downgraded, Agilon Upgraded at Citi in 2025 Health Tech Review
Citi Downgrades Hims & Hers Health(HIMS.US) to Sell Rating, Raises Target Price to $25